JP2003530431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530431A5 JP2003530431A5 JP2001576006A JP2001576006A JP2003530431A5 JP 2003530431 A5 JP2003530431 A5 JP 2003530431A5 JP 2001576006 A JP2001576006 A JP 2001576006A JP 2001576006 A JP2001576006 A JP 2001576006A JP 2003530431 A5 JP2003530431 A5 JP 2003530431A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- naphthalimide
- antiproliferative agent
- agent
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000001028 anti-proliverative effect Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- UPALIKSFLSVKIS-UHFFFAOYSA-N 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione Chemical compound NC1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 UPALIKSFLSVKIS-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 229960004701 amonafide Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- BUQLXKSONWUQAC-UHFFFAOYSA-N Parthenolide Natural products CC1C2OC(=O)C(=C)C2CCC(=C/CCC1(C)O)C BUQLXKSONWUQAC-UHFFFAOYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- KTEXNACQROZXEV-PVLRGYAZSA-N parthenolide Chemical compound C1CC(/C)=C/CC[C@@]2(C)O[C@@H]2[C@H]2OC(=O)C(=C)[C@@H]21 KTEXNACQROZXEV-PVLRGYAZSA-N 0.000 description 1
- 229940069510 parthenolide Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19710300P | 2000-04-12 | 2000-04-12 | |
| US60/197,103 | 2000-04-12 | ||
| PCT/US2001/012169 WO2001078705A2 (en) | 2000-04-12 | 2001-04-12 | Compositions containing a naphthalmide and an antiproliferative agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003530431A JP2003530431A (ja) | 2003-10-14 |
| JP2003530431A5 true JP2003530431A5 (cg-RX-API-DMAC7.html) | 2008-05-29 |
Family
ID=22728064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001576006A Withdrawn JP2003530431A (ja) | 2000-04-12 | 2001-04-12 | ナフタルイミドおよび抗増殖性剤を含有する組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6630173B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1274458B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003530431A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE305312T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU5348301A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2404278C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60113666T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2248312T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1052874B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001078705A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2267741T3 (es) * | 2000-03-15 | 2007-03-16 | Chemgenex Pharmaceuticals, Inc. | Composiciones combinadas de alcaloides de cefalotaxina y de los mismos. |
| EP1274458B1 (en) * | 2000-04-12 | 2005-09-28 | ChemGenex Pharmaceuticals, Inc. | Compositions containing a naphthalmide and an antiproliferative agent |
| US20060211648A1 (en) * | 2000-04-12 | 2006-09-21 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| US7135481B2 (en) * | 2000-04-12 | 2006-11-14 | Chemgenex Pharmaceuticals, Inc. | Naphthalimide compositions and uses thereof |
| US20050170015A1 (en) * | 2000-10-31 | 2005-08-04 | Brown Dennis M. | Antiproliferative colchicine compositions and uses thereof |
| US20050239816A1 (en) * | 2002-04-22 | 2005-10-27 | Xanthus Life Sciences, Inc. | Amonafide salts |
| US6693198B2 (en) * | 2002-04-22 | 2004-02-17 | Xanthus Life Sciences, Inc. | Amonafide salts |
| JP2005529123A (ja) * | 2002-04-24 | 2005-09-29 | リサーチ ディベロップメント ファンデーション | 核転写調節因子ＮＦ−κＢ抑制剤と抗腫瘍薬の相乗効果 |
| EP1539150A4 (en) * | 2002-07-08 | 2006-10-11 | Chemgenex Pharmaceuticals Inc | SYNTHESIS OF NAPHTHALIMIDES, INCLUDING AMONAFIDS, AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME |
| CA2492456A1 (en) * | 2002-07-17 | 2004-01-29 | Dennis M. Brown | Formulations and methods of administration of cephalotaxines, including homoharringtonine |
| WO2004009030A2 (en) * | 2002-07-22 | 2004-01-29 | Chemgenex Pharmaceuticals Limited | Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| JP2007525214A (ja) * | 2004-01-30 | 2007-09-06 | ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド | Ｎ−アセチルトランスフェラーゼ遺伝子型解析によって投与するナフタルイミド |
| CA2569279A1 (en) * | 2004-06-04 | 2005-12-15 | Chemgenex Pharmaceuticals, Inc. | Methods of treating cellular proliferative disease using naphthalimide and parp-1 inhibitors |
| CA2597323A1 (en) * | 2005-02-10 | 2006-08-17 | Chemgenex Pharmaceuticals, Inc. | Medical devices |
| CA2684219C (en) * | 2007-04-13 | 2017-05-23 | Chemgenex Pharmaceuticals, Inc. | Oral cephalotaxine dosage forms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183821A (en) * | 1983-09-19 | 1993-02-02 | Laboratories Knoll, S.A. | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors |
| US5420137A (en) | 1989-07-11 | 1995-05-30 | Knoll Ag | Amonafide salts |
| FR2673944B1 (fr) * | 1991-03-13 | 1995-03-10 | Sanofi Elf | Derives de l'1,8-naphtalimide, leur procede de preparation et les compositions pharmaceutiques les contenant. |
| JP2002511878A (ja) * | 1997-07-01 | 2002-04-16 | アセロジエニクス・インコーポレイテツド | 抗酸化剤による過増殖状態の治療の増強 |
| ES2267741T3 (es) * | 2000-03-15 | 2007-03-16 | Chemgenex Pharmaceuticals, Inc. | Composiciones combinadas de alcaloides de cefalotaxina y de los mismos. |
| JP2003531138A (ja) * | 2000-03-21 | 2003-10-21 | アセロジエニクス・インコーポレイテツド | 生物学的疾患の治療のためのｎ−置換ジチオカルバメート |
| EP1274458B1 (en) * | 2000-04-12 | 2005-09-28 | ChemGenex Pharmaceuticals, Inc. | Compositions containing a naphthalmide and an antiproliferative agent |
-
2001
- 2001-04-12 EP EP01926985A patent/EP1274458B1/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012169 patent/WO2001078705A2/en not_active Ceased
- 2001-04-12 CA CA2404278A patent/CA2404278C/en not_active Expired - Fee Related
- 2001-04-12 DE DE60113666T patent/DE60113666T2/de not_active Expired - Lifetime
- 2001-04-12 JP JP2001576006A patent/JP2003530431A/ja not_active Withdrawn
- 2001-04-12 ES ES01926985T patent/ES2248312T3/es not_active Expired - Lifetime
- 2001-04-12 HK HK03105124.5A patent/HK1052874B/en not_active IP Right Cessation
- 2001-04-12 AU AU5348301A patent/AU5348301A/xx not_active Withdrawn
- 2001-04-12 US US09/834,177 patent/US6630173B2/en not_active Expired - Fee Related
- 2001-04-12 AT AT01926985T patent/ATE305312T1/de not_active IP Right Cessation
-
2003
- 2003-07-31 US US10/631,106 patent/US20040047918A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003530431A5 (cg-RX-API-DMAC7.html) | ||
| JP2003526667A5 (cg-RX-API-DMAC7.html) | ||
| RU2737508C2 (ru) | Способы воздействия на транскрипционный контроль в суперэнхансерных областях | |
| Bischof et al. | Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro | |
| BRPI0408005A (pt) | composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor | |
| US20110166092A1 (en) | Dosing methods for treating disease | |
| JP2004500390A5 (cg-RX-API-DMAC7.html) | ||
| CA2404278A1 (en) | Naphthalimide compositions and uses thereof | |
| IS6925A (is) | Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns | |
| JP2012229273A (ja) | ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法 | |
| JP2005538129A5 (cg-RX-API-DMAC7.html) | ||
| JP2006502132A5 (cg-RX-API-DMAC7.html) | ||
| JP2009517403A5 (cg-RX-API-DMAC7.html) | ||
| Fan et al. | Evaluation of pharmacokinetic-pharmacodynamic (PKPD) relationship of an oral, selective, first-in-class, potent IDH2 inhibitor, AG-221, from a phase 1 trial in patients with advanced IDH2 mutant positive hematologic malignancies | |
| JP2015504079A (ja) | 還元型フォレート、たとえばメチレン−テトラヒドロフォレートの抗腫瘍活性 | |
| AR049136A1 (es) | Composicion y metodo con irinotecan (cpt-11) y un inhibidor del egfr,como erlotinib | |
| MXPA05009781A (es) | Potenciador de efecto antitumoral y agente antitumoral. | |
| JP2016014051A (ja) | ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置 | |
| Jennings-Gee et al. | Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP [10] anti-leukemic activity | |
| JP2005502690A5 (cg-RX-API-DMAC7.html) | ||
| WO2008002382B1 (en) | Compositions and methods for enhancing brain function | |
| Schaefer et al. | Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers | |
| WO2005007183A3 (en) | Treatment of anemia | |
| AU2001253483B2 (en) | Compositions containing a naphthalimide and an antiproliferative agent | |
| 이보람 et al. | Free Paper Presentation; The Efficacy of UFT Monotherapy in Lung Cancer According to the Histological Types |